medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2008, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2008; 6 (1)

Cutaneous amyloidosis and its treatment

Miranda GA, Frías AG, Hierro OS

Language: Spanish
References: 38
Page: 29-34
PDF size: 323.88 Kb.


ABSTRACT

The abnormal extracellular deposits of fibrous proteins of amyloid type is known as amyloidosis. This could be found in several organs or to be present just in one. When this is localized to the skin, it is known as cutaneous amyloidosis. There are three types of cutaneous amyloidosis: macular, papular or lichenoid, and nodular form. The treatment has been very disscused, at present there is no treatment of choice. We made a review and here we expose the benefits and disadvantages of each therapeutic option.


REFERENCES

  1. Breathnach, S. M., “Amyloid and amyloidosis”, J. Am. Acad. Dermatol. 1988; 18 (1): 1-16.

  2. Georgiades, C. S., E. G. Neyman, M. A. Barish y E. K. Fishman, “Amyloidosis and CT manifestations”, RadioGraphics. 2004; 24 (2): 405-416.

  3. Wong, Ch.-K., “Cutaneous amyloidoses”, Int. J. Dermatol. 1987; 26 (5): 273-277.

  4. Merlini G y V. Bellotti, “Molecular Mechanisms of Amyloidoses”, N. Eng. J. Med. 2003; 349: 583-596.

  5. Khan, M. F. y R. H. Falk, “Amyloidosis”, Postgrad. Med. J. 2001; 77: 686-693.

  6. Modiano, P. “Amyloses cutanées”, Ann. Dermatol. Venereol. 2005; 132: 62-70.

  7. Bachmeyer, C. y S. Aractingi, “Les amyloses cutanées”, Ann. Dermatol. Venereol. 2000; 127 (12): 1105-1009.

  8. Falk, R. H, R. L. Comenzo y M. Skinner, “The systemic amyloidoses”, N. Eng. J. Med. 1997; 337 (13): 898-909.

  9. Breathnach, S. M., “The cutaneous amyloidoses”, Arch. Dermatol. 1985; 121 (4): 470-474.

  10. Houman, M. H., S. M. Khanfir, I. B. Ghorbel et al., “Bullous amyloidosis”, Ann. Dermatol. Venereol. 2002; 129 (3): 299-302.

  11. Vecchietti, G., I. Masouyé, D. Salomon et al., “An unusual form of primary systemic amyloidosis: amyloid elastosis: report of a case treated by haematopoietic cell transplantation”, Br. J. Dermatol. 2003; 148: 154-159.

  12. Ming, H. J., “Biphasic cutaneous amyloidosis”, Dermatology Online J. 2001; 7 (2): 15.

  13. Hung, Ch.-Ch., Ch.-M. Wang, H. S. Hong y T.-T. Kuo, “Unusual skin manifestation of cutaneous amyloidosis”, Dermatology. 2003; 207 (1): 65-67.

  14. Hawkins, P. N., “Diagnosis and treatment of amyloidosis”, Ann. Rheum. Dis. 1997; 56: 631-633.

  15. Ollague, L. W., V. A. de Guevara y H. G. Calero, “Evolución natural de la amiloidosis cutánea primitiva”, Med. Cut. I. L. A. 1988; XVI (5): 377-379.

  16. Skinner, M., V. Sanchorawala, D. Seldin et al., “High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8 year study”, Ann. Intern. Med. 2004; 140: 85-93.

  17. Perz, J., S. O. Schonland, M. Hundemer et al., “High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study”, Br. J. Haematol. 2004; 127: 543-551.

  18. Wang, W.-J., C.-S. Lin y Ch.-K. Wong, “Response of systemic amyloidosis to dimethyl sulfoxide”, J. Am. Acad. Dermatol. 1986; 15: 402-405.

  19. Kyle, R. A, M. A. Gertz, P. R. Greipp et al., “A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicines”, N. Engl. J. Med. 1997; 336: 1202-1207.

  20. 20.Van Gameren, I. I, H. Lokhorst, B. P. C. Hazenberg y E. Vellenga, “Therapeutic options in systemic AL amyloidosis”, The Netherlands J. Med. 2004; 62 (4): 106-113.

  21. Marques, P. G., L. Goncalves y M. H. Lacerda, “Liquen amilóide com lesoes cutáneas extensas”, Med. Cut. I. L. A. 1989; XVII (2): 133-136.

  22. Bonnetblanc, J. M., G. Catanzano y J. Roux, “Dimethyl sulfoxide and macular amyloidosis”, Acta Dermatovener (Stockholm). 1980; 60: 91.

  23. Monfrecola, G., R. Iandoli, G. Bruno y D. Martellotta, “Lichen amyloidosis: a new therapeutic approach”, Acta Derm. Venereol. (Stockh). 1985; 65: 453-455. 24.Özkaya, B. E., Q. Kavak, H. Güngör y G. Özarmagan, “Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis”, Int. J. Dermatol. 1998; 37 (12): 949-954.

  24. 24.Özkaya, B. E., Q. Kavak, H. Güngör y G. Özarmagan, “Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis”, Int. J. Dermatol. 1998; 37 (12): 949-954.

  25. Lim, K. B., S. H. Tan y K. T. Tan, “Lack of effect of dimethyl sulfoxide (DMSO) on amyloid deposits in lichen amyloidosis”, Br. J. Dermatol. 1988; 119: 409-410. 26.Kobayashi, T., Y. Yamasaki, T. Watanabe y N. Onoda, “Extensive li - chen amyloidosus refractory to DMSO”, J. Dermatol. 1995; 22: 755-758.

  26. Aram, H., “Failure of etretinate in lichen amyloidosus”, Int. J. Dermatol. 1986; 25: 206.

  27. Ollague, L. W., “Primary cutaneous amyloidosis”, Int. J. Dermatol. 1987; 26 (2): 135.

  28. 29.Marschalkó, M. y J. Daróczy, “Etretinate for the treatment of lichen amyloidosis”, Arch. Dermatol. 1988; 124: 657.

  29. 30.Helander, I., “Treatment of lichen amyloidosis by etretinate”, Clin. Exp. Dermatol. 1986; 11: 574-577.

  30. Khoo, B.-P., Y.-K. Tay y Ch.-L. Goh, “Calcipotriol oinment vs. betamethasone 17-valerate oinment in the treatment of lichen amyloidosis”, Int. J. Dermatol. 1999; 38: 539-541.

  31. 32.Wong, Ch.-K. y W.-M. Li, “Dermabrasion for lichen amyloidosis”, Arch. Dermatol. 1982; 118: 302-304.

  32. Harahap, M. y M. R. Perkasa, “The treatment of lichen amyloidosis”, Dermatol. Surg. 1998; 24: 251-254.

  33. Lien, M. H., D. Railan y B. R. Nelson, “The efficacy of dermabrasion in the treatment of nodular amyloidosis”, J. Am. Acad. Dermatol. 1997; 36 (2/2): 315-316.

  34. Parsi, K. y S. Kossard, “Thermosensitive lichen amyloidosis”, Int. J. Dermatol. 2004; 43: 925-928.

  35. Behr, F., N. Levine y J. Bangert, “Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine”, Arch. Dermatol. 2001; 137 (5): 553-555.

  36. Truhan, A. P., J. M. Garden y H. H. Roenigk, “Nodular primary localized cutaneous amyloidosis: immunohistochemical evaluation and treatment with the carbon dioxide laser”, J. Am. Acad. Dermatol. 1986; 14 (6): 1058-1062.

  37. Hamzavi, I. y L. Harvey, “Excess tissue friability during CO2 laser vaporization of nodular amyloidosis”, Dermatol. Surg. 1999; (9): 726-728.

  38. Alster, T. S. y R. M. P. Manaloto, “Nodular amyloidosis treated with a pulsed dye laser”, Dermatol. Surg. 1999; 25 (2): 133-135.




2020     |     www.medigraphic.com